190 related articles for article (PubMed ID: 11583069)
1. Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.
Doggrell SA
Expert Opin Pharmacother; 2001 Jul; 2(7):1187-9. PubMed ID: 11583069
[TBL] [Abstract][Full Text] [Related]
2. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
3. [Gemfibrozil: new aspects in clinical use].
Tada N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():625-30. PubMed ID: 11347143
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
[TBL] [Abstract][Full Text] [Related]
5. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
[TBL] [Abstract][Full Text] [Related]
6. [Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study].
Scheen AJ
Rev Med Liege; 1999 Sep; 54(9):773-5. PubMed ID: 10589275
[TBL] [Abstract][Full Text] [Related]
7. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
Boden WE; Pearson TA
Am J Cardiol; 2000 Mar; 85(5):645-50, A10. PubMed ID: 11078282
[TBL] [Abstract][Full Text] [Related]
8. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
Boden WE
Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
[TBL] [Abstract][Full Text] [Related]
9. Beyond LDL-C--the importance of raising HDL-C.
Wierzbicki AS; Mikhailidis DP
Curr Med Res Opin; 2002; 18(1):36-44. PubMed ID: 11999145
[TBL] [Abstract][Full Text] [Related]
10. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
Frick MH; Syvänne M; Nieminen MS; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Taskinen MR
Circulation; 1997 Oct; 96(7):2137-43. PubMed ID: 9337181
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
[TBL] [Abstract][Full Text] [Related]
12. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.
Brousseau ME; O'Connor JJ; Ordovas JM; Collins D; Otvos JD; Massov T; McNamara JR; Rubins HB; Robins SJ; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1148-54. PubMed ID: 12117730
[TBL] [Abstract][Full Text] [Related]
13. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial.
Robins SJ
Am J Cardiol; 2001 Dec; 88(12A):19N-23N. PubMed ID: 11788126
[TBL] [Abstract][Full Text] [Related]
14. Benefits of fibrate drugs in coronary heart disease patients with normal cholesterol levels.
Havel RJ
Circulation; 1997 Oct; 96(7):2113-4. PubMed ID: 9337175
[No Abstract] [Full Text] [Related]
15. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
16. Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.
Chen MF; Wang TD; Yeh HT; Hsu HC; Lee YT
Eur J Clin Invest; 2001 Aug; 31(8):707-13. PubMed ID: 11473572
[TBL] [Abstract][Full Text] [Related]
17. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Fruchart JC; Duriez P
Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
Hay JW; Sterling KL
Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats.
Rizvi F; Iftikhar M; George JP
J Med Food; 2003; 6(2):123-8. PubMed ID: 12935323
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT
Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
